The effect of L-arginine supplementation on the levels of antioxidative enzymes and inflammatory factors in patients with Metabolic dysfunction-associated steatotic liver disease(MASLD)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230123057193N4

Enrollment

Registered

2024-10-24

Start date

2024-10-22

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic dysfunction-associated steatotic liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: The intervention group will receive 3000 mg of arginine daily (3 tablets of 1000 mg) with water for 8 weeks. Arginine tablets are purchased from Karen. All patient

Eligibility

Sex/Gender

All

Age

30 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patients with metabolic disorder related to diagnosed steatotic liver disease without fibrosis and cap score below 310 and Metavir score below f1, which has been confirmed by a gastroenterologist. Age between 30-55 BMI 25- 35

Exclusion criteria

Exclusion criteria: pregnant and lactating chronic diseases such as cardiovascular, cancer, Alzheimer's, Parkinson's, and chronic kidney disease, history of stroke and heart attack, rheumatoid arthritis, diabetes, thyroid diseases, and other chronic diseases and menopause Based on the information provided by the individual Blood Pressure Medications Thyroid Medications corticosteroids drug Drugs affecting blood glucose levels Anti-inflammatory supplements Antioxidant supplements Omega 3 consumption Taking antibiotics, antivirals and antifungals Any history of alcohol and tobacco use

Design outcomes

Primary

Measure	Time frame
Erythrocyte sedimentation rate (ESR). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;C-reactive protein (CRP). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;Superoxide dismutase (SOD). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;Catalase. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;Glutathione peroxidase (GPX). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.	—

Measure

Time frame

Erythrocyte sedimentation rate (ESR). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;C-reactive protein (CRP). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;Superoxide dismutase (SOD). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;Catalase. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;Glutathione peroxidase (GPX). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactsorayia ebrahim pour koujan

Tehran University of Medical Sciences

nutri.seam1@gmail.com+98 21 5563 0553

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026